Advertisement

Current Osteoporosis Reports

, Volume 10, Issue 1, pp 73–79 | Cite as

Inhibition of Cathepsin K for Treatment of Osteoporosis

  • Steven Boonen
  • Elizabeth Rosenberg
  • Frank Claessens
  • Dirk Vanderschueren
  • Socrates Papapoulos
Future Therapeutics (P Miller, Section Editor)

Abstract

Cathepsin K is the protease that is primarily responsible for the degradation of bone matrix by osteoclasts. Inhibitors of cathepsin K are in development for treatment of osteoporosis. Currently available antiresorptive drugs interfere with osteoclast function. They inhibit both bone resorption and formation, due to the coupling between these processes. Cathepsin K inhibitors, conversely, target the resorption process itself and may not interfere with osteoclast stimulation of bone formation. In fact, when cathepsin K is absent or inhibited in mice, rabbits, or monkeys, bone formation is maintained or increased. In humans, inhibition of cathepsin K is associated with sustained reductions in bone resorption markers but with smaller and transient reductions in bone formation markers. The usefulness of cathepsin K inhibitors in osteoporosis is now being examined in phase 2 and phase 3 clinical trials of postmenopausal osteoporotic women.

Keywords

Cathepsin K inhibition Osteoporosis 

Notes

Disclosure

Conflicts of interest: S. Boonen: received editorial support from Dr. Rosenberg who is an employee of Merck; has received payment for lectures including service on speakers bureaus for Amgen, Novartis, and Servier; and has received travel/accommodations/meeting expenses from Amgen, Novartis, and Servier for Congress participation; E. Rosenberg: is employed by and has stock options in Merck Sharp & Dohme; F. Claessens: none; D. Vanderschueren: none; S. Papapoulos: has been a board member for Merck & Co Advisory Board, Amgen, Novartis; has been a consultant for Merck & Co, Alliance for Better Bone Health, Amgen, Roche, GlaxoSmithKline; and has received honoraria from all above-mentioned entities in relation to participation in AdB and Consultancies; and has received travel/accommodations expenses covered or reimbursed from all above-mentioned entities in relation to participation in AdB.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet. 2011;377:1276–87.PubMedCrossRefGoogle Scholar
  2. 2.
    Sambrook P, Cooper C. Osteoporosis. Lancet. 2006;367:2010–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002;359:1761–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Fast Facts. nof.org/node/40. Accessed 7 June 2011.Google Scholar
  5. 5.
    Teitelbaum SL. Bone resorption by osteoclasts. Science. 2000;289:1504–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Vaananen HK, Laitala-Leinonen T. Osteoclast lineage and function. Arch Biochem Biophys. 2008;473:132–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Lecaille F, Bromme D, Lalmanach G. Biochemical properties and regulation of cathepsin K activity. Biochimie. 2008;90:208–26.PubMedCrossRefGoogle Scholar
  8. 8.
    Karsdal MA, Martin TJ, Bollerslev J, et al. Are nonresorbing osteoclasts sources of bone anabolic activity? J Bone Miner Res. 2007;22:487–94.PubMedCrossRefGoogle Scholar
  9. 9.
    Henriksen K, Neutzsky-Wulff AV, Bonewald LF, Karsdal MA. Local communication on and within bone controls bone remodeling. Bone. 2009;44:1026–33.PubMedCrossRefGoogle Scholar
  10. 10.
    Matsuo K, Irie N. Osteoclast-osteoblast communication. Arch Biochem Biophys. 2008;473:201–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys. 2008;473:139–46.PubMedCrossRefGoogle Scholar
  12. 12.
    Fuller K, Lawrence KM, Ross JL, et al. Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts. Bone. 2008;42:200–11.PubMedCrossRefGoogle Scholar
  13. 13.
    Tang Y, Wu X, Lei W, et al. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med. 2009;15:757–65.PubMedCrossRefGoogle Scholar
  14. 14.
    Pasquale EB. Eph-ephrin bidirectional signaling in physiology and disease. Cell. 2008;133:38–52.PubMedCrossRefGoogle Scholar
  15. 15.
    Zhao C, Irie N, Takada Y, et al. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab. 2006;4:111–21.PubMedCrossRefGoogle Scholar
  16. 16.
    Segovia-Silvestre T, Neutzsky-Wulff AV, Sorensen MG, et al. Advances in osteoclast biology resulting from the study of osteopetrotic mutations. Hum Genet. 2009;124:561–77.PubMedCrossRefGoogle Scholar
  17. 17.
    Drake FH, Dodds RA, James IE, et al. Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J Biol Chem. 1996;271:12511–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Bromme D, Okamoto K, Wang BB, Biroc S. Human cathepsin O2, a matrix protein-degrading cysteine protease expressed in osteoclasts. Functional expression of human cathepsin O2 in Spodoptera frugiperda and characterization of the enzyme. J Biol Chem. 1996;271:2126–32.PubMedCrossRefGoogle Scholar
  19. 19.
    Garnero P, Borel O, Byrjalsen I, et al. The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem. 1998;273:32347–52.PubMedCrossRefGoogle Scholar
  20. 20.
    Gelb BD, Shi GP, Chapman HA, Desnick RJ. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science. 1996;273:1236–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Schilling AF, Mulhausen C, Lehmann W, et al. High bone mineral density in pycnodysostotic patients with a novel mutation in the propeptide of cathepsin K. Osteoporos Int. 2007;18:659–69.PubMedCrossRefGoogle Scholar
  22. 22.
    Ho N, Punturieri A, Wilkin D, et al. Mutations of CTSK result in pycnodysostosis via a reduction in cathepsin K protein. J Bone Miner Res. 1999;14:1649–53.PubMedCrossRefGoogle Scholar
  23. 23.
    Saftig P, Hunziker E, Wehmeyer O, et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci U S A. 1998;95:13453–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Gowen M, Lazner F, Dodds R, et al. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res. 1999;14:1654–63.PubMedCrossRefGoogle Scholar
  25. 25.
    Li CY, Jepsen KJ, Majeska RJ, et al. Mice lacking cathepsin K maintain bone remodeling but develop bone fragility despite high bone mass. J Bone Miner Res. 2006;21:865–75.PubMedCrossRefGoogle Scholar
  26. 26.
    Pennypacker B, Shea M, Liu Q, et al. Bone density, strength, and formation in adult cathepsin K (-/-) mice. Bone. 2009;44:199–207.PubMedCrossRefGoogle Scholar
  27. 27.
    Kiviranta R, Morko J, Uusitalo H, et al. Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K. J Bone Miner Res. 2001;16:1444–52.PubMedCrossRefGoogle Scholar
  28. 28.
    Yasuda Y, Kaleta J, Bromme D. The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. Adv Drug Deliv Rev. 2005;57:973–93.PubMedCrossRefGoogle Scholar
  29. 29.
    Stoch SA, Wagner JA. Cathepsin K inhibitors: a novel target for osteoporosis therapy. Clin Pharmacol Ther. 2008;83:172–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Yamashita DS, Marquis RW, Xie R, et al. Structure activity relationships of 5-, 6-, and 7-methyl-substituted azepan-3-one cathepsin K inhibitors. J Med Chem. 2006;49:1597–612.PubMedCrossRefGoogle Scholar
  31. 31.
    Gauthier JY, Chauret N, Cromlish W, et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett. 2008;18:923–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Adami S, Supronik J, Hala T, et al. Effect of 1 year treatment with the Cathepsin-K inhibitor, balicatib, on bone mineral density (BMD) in postmenopausal women with osteopenia/osteoporosis. J Bone Miner Res. 2006;21(Suppl S1):S24. Abstract 1085.Google Scholar
  33. 33.
    Peroni A, Zini A, Braga V, et al. Drug-induced morphea: report of a case induced by balicatib and review of the literature. J Am Acad Dermatol. 2008;59:125–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Runger TM, Adami S, Benhamou CL, et al. Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib. J Am Acad Dermatol. 2011. doi: 10.1016/j.jaad2010.11.033
  35. 35.
    Pennypacker BL, Duong lT, Cusick TE, et al. Cathepsin K inhibitors prevent bone loss in estrogen-deficient rabbits. J Bone Miner Res. 2011;26:252–62.PubMedCrossRefGoogle Scholar
  36. 36.
    Stroup GB, Kumar S, Jerome CP. Treatment with a potent cathepsin K inhibitor preserves cortical and trabecular bone mass in ovariectomized monkeys. Calcif Tissue Int. 2009;85:344–55.PubMedCrossRefGoogle Scholar
  37. 37.
    • Masarachia PJ, Pennypacker B, Pickarski M, et al. Odanacatib reduces bone turnover and increases bone mass in lumbar spine of skeletally mature ovariectomized rhesus monkeys. J Bone Miner Res. 2011, in press. Uses non-human primates to explore the mechanism of action of cathepsin K inhibitors for osteoporosis.Google Scholar
  38. 38.
    Yamada H, Mori H, Kunishige A, et al. Efficacy of ONO-5334, a cathepsin K inhibitor, on bone turnover markers and bone mineral density in ovariectomized cynomolgus monkeys. Presented at European Calicified Tissue International, Glasgow, Scottland; 2010.Google Scholar
  39. 39.
    Yamada H, Ochi Y, Kunishige A, et al. Efficacy of ONO-5334, a cathepsin K inhibitor, on bone mass and strength in ovariectomized cynomolgus monkeys. Bone. 2011;48:S221.CrossRefGoogle Scholar
  40. 40.
    Ochi Y, Yamada H, Kunishige ANS, et al. Efficacy of ONO-5334, a cathepsin K inhibitor, on bone turnover and cortical geometry in ovariectomized cynolmolgus monkeys. Bone. 2011;48:S72.CrossRefGoogle Scholar
  41. 41.
    Mayhew PM, Thomas CD, Clement JG, et al. Relation between age, femoral neck cortical stability, and hip fracture risk. Lancet. 2005;366:129–35.PubMedCrossRefGoogle Scholar
  42. 42.
    • Jerome C, Missbach M, Gamse R. Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys. Osteoporos Int. 2011.Google Scholar
  43. 43.
    • Cusick T, Chen CM, Pennypacker BL, et al. Odanacatib treatment increases Hi bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in ovariectomized adult rhesus monkey. J Bone Miner Res. 2011, in press. Uses non-human primates to explore the mechanism of action of cathepsin K inhibitors for osteoporosis.Google Scholar
  44. 44.
    •• Bone HG, McClung MR, Roux C, et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res. 2010;25:937–47. Reports clinical results of drugs in development that use the novel mechanism of action of inhibition of cathepsin K.PubMedGoogle Scholar
  45. 45.
    •• Eisman JA, Bone HG, Hosking DJ, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res. 2011;26:242–51. Reports clinical results of drugs in development that use the novel mechanism of action of inhibition of cathepsin K.PubMedCrossRefGoogle Scholar
  46. 46.
    Binkley N, Bone H, Gilcrist N, et al. Treatment with the cathepsin K inhibitor odanacatib in postmenopausal women with low BMD: 5 year results of a phase 2 trial. Presented at the American Society of Bone and Mineral Research, San Diego, CA; 2011.Google Scholar
  47. 47.
    Bone H, Dempster D, Eisman J, et al. Phase 3 fracture trial of odanacatib for osteoporosis - study design. Presented at the Endocrine Society meeting, San Diego, CA; 2010.Google Scholar
  48. 48.
    •• Eastell R, Nagase S, Ohyama M, et al. Safety and efficacy of the Cathepsin K inhibitor, ONO-5334, in postmenopausal osteoporosis - the OCEAN study. J Bone Miner Res. 2011;26:1303–12. Reports clinical results of drugs in development that use the novel mechanism of action of inhibition of cathepsin K.PubMedCrossRefGoogle Scholar
  49. 49.
    Eastell R, Nagase S, Small M, et al. Effect of the cathepsin K inhibitor ONO-5334 on biochemical markers of bone turnover in the treatment of postmennopausal osteopenia or osteoporosis: 2-year results from the OCEAN atudy. J Bone Miner Res. 2011.Google Scholar
  50. 50.
    Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999;282:1344–52.PubMedCrossRefGoogle Scholar
  51. 51.
    Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296:2927–38.PubMedCrossRefGoogle Scholar
  52. 52.
    Gallagher JC, Rapuri PB, Haynatzki G, Detter JR. Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. J Clin Endocrinol Metab. 2002;87:4914–23.PubMedCrossRefGoogle Scholar
  53. 53.
    Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008;43:222–9.PubMedCrossRefGoogle Scholar
  54. 54.
    Stakkestad JA, Lakatos P, Lorenc R, et al. Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension. Clin Rheumatol. 2008;27:955–60.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Steven Boonen
    • 1
  • Elizabeth Rosenberg
    • 2
  • Frank Claessens
    • 3
  • Dirk Vanderschueren
    • 4
  • Socrates Papapoulos
    • 5
  1. 1.Leuven University Division of Geriatric Medicine and Centre for Metabolic Bone DiseasesLeuvenBelgium
  2. 2.Merck Sharp & Dohme Corp.Whitehouse StationUSA
  3. 3.Leuven University Department of Molecular Cell BiologyLeuvenBelgium
  4. 4.Leuven University Department of Andrology and EndocrinologyLeuvenBelgium
  5. 5.Leiden University Medical CenterLeidenNetherlands

Personalised recommendations